Expertise in
12
conditions

Nobuhisa Ishikawa

Hiroshima, JP 
Expertise in
12
conditions
Hiroshima, JP 

Overview

Nobuhisa Ishikawa practices practicing medicine in Hiroshima, Japan.

Ishikawa is highly rated in 12 conditions, according to our data. Their clinical expertise encompasses Lung Cancer, Interstitial Lung Disease, Acute Interstitial Pneumonia, and Non-Small Cell Lung Cancer (NSCLC).

They are actively involved in clinical research, co-authoring 77 peer reviewed articles and participating in 5 clinical trials.

Locations

Hiroshima, Japan
Other Locations
Minami, 7348530, Japan
Izumo, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: May 18, 2026
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
Japanese Idiopathic Interstitial Pneumonias Registry
Japanese Idiopathic Interstitial Pneumonias Registry
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2026
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Biological
Study Drug: Depemokimab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Prospective, Epidemiological, Cohort Study to Assess the Aetiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease in Japan
A Prospective, Epidemiological, Cohort Study to Assess the Aetiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease in Japan
Enrollment Status: Completed
Publish Date: February 22, 2024
Intervention Type: Other
View 4 Less Clinical Trials

77 Total Publications

Takayasu Arteritis in a Middle-aged Woman Following Prolonged Subsequent Fever after COVID-19 Infection: An Early Diagnosis Using Contrast-enhanced CT.
Takayasu Arteritis in a Middle-aged Woman Following Prolonged Subsequent Fever after COVID-19 Infection: An Early Diagnosis Using Contrast-enhanced CT.
Journal: Internal medicine (Tokyo, Japan)
Published: January 14, 2026

Frequently Asked Questions about Nobuhisa Ishikawa

Is Nobuhisa Ishikawa a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Nobuhisa Ishikawa is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Nobuhisa Ishikawa participate in research or clinical trials?

Yes. Nobuhisa Ishikawa has published 77 articles and abstracts on conditions like Lung Cancer. You can view a list of Nobuhisa Ishikawa's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ishikawa's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 18 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile